MX362094B - Marcadores de diagnostico para el tratamiento de trastornos proliferativos celulares con inhibidores de telomerasa. - Google Patents
Marcadores de diagnostico para el tratamiento de trastornos proliferativos celulares con inhibidores de telomerasa.Info
- Publication number
- MX362094B MX362094B MX2015006538A MX2015006538A MX362094B MX 362094 B MX362094 B MX 362094B MX 2015006538 A MX2015006538 A MX 2015006538A MX 2015006538 A MX2015006538 A MX 2015006538A MX 362094 B MX362094 B MX 362094B
- Authority
- MX
- Mexico
- Prior art keywords
- cell proliferative
- proliferative disorders
- diagnostic markers
- telomerase inhibitors
- treating cell
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/91245—Nucleotidyltransferases (2.7.7)
- G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
- G01N2333/9128—RNA-directed DNA polymerases, e.g. RT (2.7.7.49)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
Abstract
La presente invención se refiere a métodos para identificar individuos diagnosticados con un trastorno proliferativo celular que se beneficiarán del tratamiento con un compuesto inhibidor de telomerasa. También se proporcionan en la presente métodos para el tratamiento de estos individuos con compuestos inhibidores de telomerasa.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261732263P | 2012-11-30 | 2012-11-30 | |
US201361780851P | 2013-03-13 | 2013-03-13 | |
US13/802,035 US9200327B2 (en) | 2012-11-30 | 2013-03-13 | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
US201361798478P | 2013-03-15 | 2013-03-15 | |
US201361809228P | 2013-04-05 | 2013-04-05 | |
PCT/US2013/072302 WO2014085632A1 (en) | 2012-11-30 | 2013-11-27 | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015006538A MX2015006538A (es) | 2015-09-23 |
MX362094B true MX362094B (es) | 2019-01-07 |
Family
ID=50828470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015006538A MX362094B (es) | 2012-11-30 | 2013-11-27 | Marcadores de diagnostico para el tratamiento de trastornos proliferativos celulares con inhibidores de telomerasa. |
Country Status (24)
Country | Link |
---|---|
EP (3) | EP3495495B1 (es) |
JP (2) | JP6359028B2 (es) |
KR (3) | KR102174763B1 (es) |
CN (2) | CN111494629A (es) |
AU (3) | AU2013352105B2 (es) |
BR (1) | BR112015012507B1 (es) |
CA (1) | CA2892445C (es) |
CY (1) | CY1124140T1 (es) |
DK (2) | DK2925889T3 (es) |
ES (3) | ES2865446T3 (es) |
HK (1) | HK1215874A1 (es) |
HR (2) | HRP20181991T1 (es) |
HU (1) | HUE054053T2 (es) |
IL (3) | IL282112B (es) |
LT (2) | LT3495495T (es) |
MX (1) | MX362094B (es) |
NZ (2) | NZ708654A (es) |
PL (2) | PL3495495T3 (es) |
PT (2) | PT3495495T (es) |
RS (1) | RS61513B1 (es) |
SG (1) | SG11201504209YA (es) |
SI (2) | SI3495495T1 (es) |
WO (1) | WO2014085632A1 (es) |
ZA (2) | ZA201900759B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3029154B1 (en) | 2008-10-17 | 2017-10-04 | Geron Corporation | Method for identification of sensitivity of a patient to telomerase inhibition therapy |
US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
JPWO2018207952A1 (ja) * | 2017-05-12 | 2020-04-16 | 国立大学法人九州大学 | 発毛及び/又は育毛用組成物 |
KR20210038895A (ko) * | 2018-07-31 | 2021-04-08 | 제론 코포레이션 | 텔로머라제 억제제에 의한 치료로부터 이익일 것 같은 환자를 확인하는 방법 |
GB201818792D0 (en) * | 2018-11-19 | 2019-01-02 | Telonostix Ltd | Compounds for telomere length-related treatment of cancer |
EP3674418A1 (en) * | 2018-12-26 | 2020-07-01 | Life Length S.L. | Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases |
CN114306602B (zh) * | 2020-09-28 | 2024-06-11 | 中国科学院上海营养与健康研究所 | 靶向tert在调节皮肤及毛发色素中的应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
CA2274586A1 (en) | 1996-12-20 | 1998-07-02 | Geron Corporation | Methods for detecting and inhibiting the rna component of telomerase |
JPH11276182A (ja) * | 1997-12-26 | 1999-10-12 | Chugai Pharmaceut Co Ltd | 逆転写酵素モチーフを有する新規遺伝子 |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
US7695904B2 (en) | 2002-01-31 | 2010-04-13 | University Of Utah Research Foundation | Reducing non-target nucleic acid dependent amplifications: amplifying repetitive nucleic acid sequences |
US20040234961A1 (en) * | 2002-04-22 | 2004-11-25 | Fordyce Colleen A. | Telomere length determination and applications |
EP1585974B1 (en) | 2003-01-24 | 2013-02-27 | University of Utah | Methods of predicting mortality risk by determining telomere length |
AU2004271215B2 (en) | 2003-09-09 | 2009-07-16 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
US7485717B2 (en) | 2004-07-02 | 2009-02-03 | Geron Corporation | Synthesis of protected 3′-amino nucleoside monomers |
CN104997783A (zh) * | 2005-03-25 | 2015-10-28 | Alt解决方案公司 | 端粒酶阳性细胞中端粒长度的调节和癌症治疗 |
WO2006113470A2 (en) * | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
EP3029154B1 (en) * | 2008-10-17 | 2017-10-04 | Geron Corporation | Method for identification of sensitivity of a patient to telomerase inhibition therapy |
US9689028B2 (en) | 2008-12-22 | 2017-06-27 | University Of Utah Foundation | Monochrome multiplex quantitative PCR |
US20110207128A1 (en) | 2010-02-16 | 2011-08-25 | Cawthon Richard M | Methods and kits for determining biological age and longevity based on gene expression profiles |
WO2012135125A1 (en) * | 2011-03-28 | 2012-10-04 | Geron Corporation | Telomere length measurement in formalin-fixed, paraffin embedded (ffpe) samples by quantitative pcr |
-
2013
- 2013-11-27 CA CA2892445A patent/CA2892445C/en active Active
- 2013-11-27 WO PCT/US2013/072302 patent/WO2014085632A1/en active Application Filing
- 2013-11-27 MX MX2015006538A patent/MX362094B/es active IP Right Grant
- 2013-11-27 ES ES18192236T patent/ES2865446T3/es active Active
- 2013-11-27 IL IL282112A patent/IL282112B/en unknown
- 2013-11-27 PT PT181922360T patent/PT3495495T/pt unknown
- 2013-11-27 CN CN201911349502.4A patent/CN111494629A/zh active Pending
- 2013-11-27 KR KR1020157017235A patent/KR102174763B1/ko active IP Right Grant
- 2013-11-27 PL PL18192236T patent/PL3495495T3/pl unknown
- 2013-11-27 HU HUE18192236A patent/HUE054053T2/hu unknown
- 2013-11-27 ES ES13858528T patent/ES2703914T3/es active Active
- 2013-11-27 KR KR1020217027659A patent/KR20210112394A/ko not_active Application Discontinuation
- 2013-11-27 LT LTEP18192236.0T patent/LT3495495T/lt unknown
- 2013-11-27 RS RS20210254A patent/RS61513B1/sr unknown
- 2013-11-27 PT PT13858528T patent/PT2925889T/pt unknown
- 2013-11-27 SI SI201331864T patent/SI3495495T1/sl unknown
- 2013-11-27 SI SI201331271T patent/SI2925889T1/sl unknown
- 2013-11-27 EP EP18192236.0A patent/EP3495495B1/en active Active
- 2013-11-27 NZ NZ708654A patent/NZ708654A/en unknown
- 2013-11-27 LT LTEP13858528.6T patent/LT2925889T/lt unknown
- 2013-11-27 ES ES20214086T patent/ES2972330T3/es active Active
- 2013-11-27 PL PL13858528T patent/PL2925889T3/pl unknown
- 2013-11-27 JP JP2015545446A patent/JP6359028B2/ja active Active
- 2013-11-27 SG SG11201504209YA patent/SG11201504209YA/en unknown
- 2013-11-27 DK DK13858528.6T patent/DK2925889T3/da active
- 2013-11-27 AU AU2013352105A patent/AU2013352105B2/en active Active
- 2013-11-27 KR KR1020207031441A patent/KR102348240B1/ko active IP Right Grant
- 2013-11-27 EP EP13858528.6A patent/EP2925889B1/en active Active
- 2013-11-27 CN CN201380070816.5A patent/CN104937110A/zh active Pending
- 2013-11-27 EP EP20214086.9A patent/EP3882355B1/en active Active
- 2013-11-27 DK DK18192236.0T patent/DK3495495T3/da active
- 2013-11-27 NZ NZ748624A patent/NZ748624A/en unknown
- 2013-11-27 BR BR112015012507-7A patent/BR112015012507B1/pt active IP Right Grant
-
2015
- 2015-05-27 IL IL239035A patent/IL239035B/en active IP Right Grant
-
2016
- 2016-04-01 HK HK16103783.7A patent/HK1215874A1/zh unknown
-
2018
- 2018-02-13 JP JP2018022923A patent/JP2018099127A/ja active Pending
- 2018-11-27 HR HRP20181991TT patent/HRP20181991T1/hr unknown
-
2019
- 2019-02-06 ZA ZA2019/00759A patent/ZA201900759B/en unknown
- 2019-11-13 IL IL270636A patent/IL270636B/en active IP Right Grant
- 2019-12-18 AU AU2019283840A patent/AU2019283840A1/en not_active Abandoned
-
2021
- 2021-02-26 ZA ZA2021/01317A patent/ZA202101317B/en unknown
- 2021-03-17 HR HRP20210451TT patent/HRP20210451T1/hr unknown
- 2021-03-23 CY CY20211100256T patent/CY1124140T1/el unknown
-
2022
- 2022-04-28 AU AU2022202808A patent/AU2022202808A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ708654A (en) | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors | |
EA201300810A1 (ru) | Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек | |
PH12014500995A1 (en) | Pak inhibitors for the treatment of cell proliferative disorders | |
MX2016005159A (es) | Metodos de diagnostico y tratamiento de trastornos eosinofilicos. | |
EA201490814A1 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
IN2015DN00438A (es) | ||
HK1223923A1 (zh) | 用於治療癌症的作為 突變體抑制劑的 -或 -二氨基嘧啶化合物 | |
MX2014011500A (es) | Diagnosticos y tratamientos relacionados a inhibidores her3. | |
MX2015000008A (es) | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. | |
MX2019010098A (es) | Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico. | |
WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
MX2016001439A (es) | Composiciones y metodos para identificar un riesgo de cancer en un sujeto. | |
WO2013081645A3 (en) | Erbb3 mutations in cancer | |
MX369175B (es) | Métodos para detectar mutantes de akt resistentes a fármacos. | |
MX2015012043A (es) | Agonistas muscarinicos. | |
EP2932273A4 (en) | METHODS OF DIAGNOSING AND TREATING PROSTATE CANCER | |
MX352296B (es) | Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades. | |
WO2013040504A3 (en) | Srpx for treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |